Publications
47
Citations
1,454
Est. group size
~7
Recurring co-author estimate
Active years
15
Publishing since 2012
Typically publishes in teams of ~8 · 7% small-team papers (≤3 authors) · across 13 venues
- Epidemiological impact of a 20- or 21-valent pneumococcal conjugate vaccine in the Japan adult population: insights from a dynamic transmission model
Figshare · 2026
- Epidemiological impact of a 20- or 21-valent pneumococcal conjugate vaccine in the Japan adult population: insights from a dynamic transmission model
Figshare · 2026
- Epidemiological impact of a 20- or 21-valent pneumococcal conjugate vaccine in the Japan adult population: insights from a dynamic transmission model
Expert Review of Vaccines · 2026
- Epidemiological impact of a 20- or 21-valent pneumococcal conjugate vaccine in the Japan adult population: insights from a dynamic transmission model
Figshare · 2026
- Health impact and cost-effectiveness analysis of introducing a national immunization program with 21-valent versus 20-valent pneumococcal conjugate vaccines for adults ≥65 years of age in Denmark
Figshare · 2026
- Health impact and cost-effectiveness analysis of introducing a national immunization program with 21-valent versus 20-valent pneumococcal conjugate vaccines for adults ≥ 65 years of age in Denmark
Figshare · 2026
- Health impact and cost-effectiveness analysis of introducing a national immunization program with 21-valent versus 20-valent pneumococcal conjugate vaccines for adults ≥65 years of age in Denmark
Expert Review of Pharmacoeconomics & Outcomes Research · 2026
- Health impact and cost-effectiveness analysis of introducing a national immunization program with 21-valent versus 20-valent pneumococcal conjugate vaccines for adults ≥65 years of age in Denmark
Figshare · 2026
- Modelling the Epidemiological Impact of Different Adult Pneumococcal Vaccination Strategies in the United Kingdom
Infectious Diseases and Therapy · 2025
- A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States
PLoS ONE · 2025
- PCV13-Serotype Breakthrough Pneumococcal Disease in Infants Receiving High-Valency Conjugate Vaccines: Population-Level Modeling in France
Infectious Diseases and Therapy · 2025
- Epidemiological Impact of Increasing Vaccination Coverage Rate and Re-Vaccination on Pneumococcal Disease in Older Adults in Germany
Vaccines · 2025
- P-58. Quantifying the impact of introducing a new adult-focused PCV in the United States
Open Forum Infectious Diseases · 2025
- P-617. Estimating Pediatric Breakthrough Disease from Pneumococcal Vaccines in France
Open Forum Infectious Diseases · 2025
- P-12. Evaluating the Epidemiological Impact of Lowering the Recommended Age for Adult Pneumococcal Vaccination in the United States
Open Forum Infectious Diseases · 2025
- medRxiv×8
- Open Forum Infectious Diseases×6
- Figshare×6
- Infectious Diseases and Therapy×2
- Nature Ecology & Evolution×2
- Rachel Truscon
Medicine · University of Michigan
- Yuwei Zhu
Medicine · University of Michigan
- Amy P. Callear
Medicine · University of Michigan
- Emileigh Johnson
Medicine · University of Michigan
- Geoffrey A. Weinberg
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile